Dermata Therapeutics, Inc. (NASDAQ:DRMAW) Sees Significant Decrease in Short Interest

Dermata Therapeutics, Inc. (NASDAQ:DRMAW) saw a large decline in short interest in July. As of July 31st, there was short interest totaling 480 shares, a decline of 88.6% from the July 15th total of 4,197 shares. Based on an average daily trading volume, of 7,524 shares, the days-to-cover ratio is presently 0.1 days.

Dermata Therapeutics Stock Down 12.5%

NASDAQ DRMAW traded down $0.00 during trading on Wednesday, hitting $0.00. 47,057 shares of the company’s stock were exchanged, compared to its average volume of 10,802. Dermata Therapeutics has a fifty-two week low of $0.00 and a fifty-two week high of $0.03. The stock’s 50 day moving average price is $0.01 and its two-hundred day moving average price is $0.01.

Dermata Therapeutics Company Profile

Dermata Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted therapies for inflammatory skin diseases. The company leverages small-molecule approaches to modulate key immune and cellular pathways in dermatologic conditions that currently lack effective or safe long-term treatments. Headquartered in Cambridge, Massachusetts, Dermata is advancing novel programs designed to address both common and severe skin disorders.

The company’s lead pipeline includes a selective topical PI3Kδ inhibitor being evaluated for the treatment of atopic dermatitis, where dysregulated immune signaling drives chronic inflammation and barrier dysfunction.